Longeveron Announces Clinical Collaboration To Study Cell Therapy Aging Treatment In Japan: Why It Matters
Longeveron Inc. (NASDAQ: LGVN) announced Friday a clinical trial collaboration to study its lead investigational asset, Lomecel-B.
EXCLUSIVE: Longeveron Reports Co. Entered Into Sponsored Clinical Research Deal With Japan’s National Center For Geriatrics And Gerontology, Juntendo University Hospital To Explore Safety, Efficacy Of Lomecel-B In Older Subjects
Longeveron Inc. (NASDAQ:LGVN)
("Longeveron" or the "Company"), a clinical stage biotechnology company
developing cellular therapies for chronic aging-related and certain life-threatening
conditions,
28 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
Engine Gaming and Media, Inc. (NASDAQ: GAME) rose 51% to $4.80 in pre-market trading after the company reported Q4 2021 and FY21 revenue was higher year over year.
56 Biggest Movers From Yesterday
Gainers
Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).
Mid-Morning Market Update: Markets Mostly Lower; Best Buy Posts Upbeat Q3 Earnings
Following the market opening Tuesday, the Dow traded up 0.02% to 35,627.53 while the NASDAQ fell 0.58% to 15,762.28. The S&P also fell, dropping 0.14% to 4,676.49.
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.